Company Reports

Recent Updates

All Reports

Company Report

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, including inflation and weak medical utilization trends just after making the large Hillrom acquisition. However, elevated medical utilization, supply chain pressures easing, new contracts with group purchasing organizations coming online, and a new management team onboard since then; Baxter's profits should be in turnaround mode.
Company Report

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, including inflation and weak medical utilization trends just after making the large Hillrom acquisition. However, elevated medical utilization, supply chain pressures easing, and new contracts with group purchasing organizations coming online since then, Baxter's profits should be in turnaround mode.
Stock Analyst Note

Baxter's first-quarter results included a 1% sales decline on an organic basis, against a tough comparable period, and adjusted earnings per share of $0.36 on a continuing basis, which came in above FactSet consensus of $0.31. Management maintained its guidance for 2026.
Company Report

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, supply chain pressures easing, and new contracts with group purchasing organizations coming online, Baxter's profits remain in turnaround mode.
Company Report

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, supply chain pressures easing, and new contracts with group purchasing organizations coming online, Baxter's profits remain in turnaround mode.
Stock Analyst Note

Baxter reported third-quarter results that included 41% growth in adjusted earnings per share to $0.69, which exceeded FactSet's consensus of $0.60. New management reduced its 2025 EPS guidance by 3% at the midpoint, which implies a much weaker fourth quarter than expected, and cut the dividend.
Company Report

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, supply chain pressures easing, and new contracts with group purchasing organizations coming online, Baxter's profits remain in turnaround mode.
Company Report

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, supply chain pressures easing, and new contracts with group purchasing organizations coming online, Baxter's profits remain in turnaround mode.
Company Report

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, supply chain pressures easing, and new contracts with group purchasing organizations coming up, Baxter's profits looked set for a turnaround until new US tariffs cast uncertainty around those prospects.
Company Report

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, supply chain pressures easing, and new contracts with group purchasing organizations coming up, Baxter's profits looked set for a turnaround until new US tariffs cast uncertainty around those prospects.

Sponsor Center